GLP1 agonists DA-JC4, dulaglutide, exenatide and liraglutide reduce tau hyperphosphorylation in hyperhomocysteinemia and STZ-induced sporadic AD [56–60], with dulaglutide and liraglutide also preventing neurofilament H/M hyperphosphorylation [59, 60]. Here, MAPT is linked to hyperhomocysteinemia.